Splenic marginal zone lymphoma with or without villous lymphocytes: Hematologic findings and outcomes in a series of 57 patients

Cancer

Volumn 101, Issue 9, 2004, Pages 2050-2057

  Iannitto, Emilio ^a,c   Ambrosetti, Achille ^b   Ammatuna, Emanuele ^a   Colosio, Maura ^b   Florena, Ada M ^a   Tripodo, Claudio ^a   Minardi, Viviana ^a   Calvaruso, Giuseppina ^a   Mitra, Maria Enza ^a   Pizzolo, Giovanni ^b   Menestrina, Fabio ^b   Franco, Vito ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Bone marrow biopsy; Intrasinusoidal; Splenectomy; Splenic lymphoma with villous lymphocytes; Splenic marginal zone lymphoma

Indexed keywords

ALKYLATING AGENT; PENTOSTATIN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW; CANCER SURVIVAL; CELL INFILTRATION; CLINICAL FEATURE; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTOSIS; LEUKOPENIA; LYMPHADENOMEGALY; LYMPHADENOPATHY; LYMPHOCYTE; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; SEROLOGY; SPLENECTOMY; SPLENIC MARGINAL ZONE LYMPHOMA; SPLENOMEGALY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; VILLOUS LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA; MALE; MIDDLE AGED; SPLENECTOMY; SPLENIC NEOPLASMS; SURVIVAL RATE;

EID: 7044286173     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20596     Document Type: Article

References (25)

1. Schmid C, Kirkham N, Diss T, et al. Splenic marginal zone cell lymphoma. Am J Surg Pathol. 1992;16:455-466.
2. Isaacson PG, Piris MA, Catovsky D, et al. Splenic marginal zone lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. Tumors of haematopoietic and lymphoid tissues. World Health Organization classification of tumors. Lyon: IARC Press, 2001:135-137.
3. Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003;101:2464-2472.
4. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-1956.
5. Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol. 1999;36:148-154.
6. Matutes E, Morilla R, Owusu-Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83:1558-1562.
7. Gruszka-Westwood AM, Matutes E, Coignet LJ, Wotherspoon A, Catovsky D. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol. 1999;104:600-604.
8. Mateo M, Mollejo M, Villuendas R, et al. 7q31-32 allelic loss is a frequent finding in splenic marginal zone lymphoma. Am J Pathol 1999;154:1583-1589.
9. Franco V, Florena AM, Campesi G. Intrasinusoidal bone marrow infiltration: a possible hallmark of splenic lymphoma. Histopathology. 1996;29:571-575.
10. Costes V, Duchayne E, Taib J, et al. Intrasinusoidal bone marrow infiltration: a common growth pattern for different lymphoma subtypes. Br J Haematol. 2002;119:916-922.
11. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994;84:3828-3834.
12. Arcaini L, Paulli M, Boveri E, et al. Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles. Cancer. 2004;100:107-115.
13. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol. 2003;120:759-764.
14. Troussard X, Valensi F, Duchayne E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol. 1996;93:731-736.
15. Chacon JI, Mollejo M, Munoz E, et al. Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. Blood. 2002;100:1648-1654.
16. Thieblemont C, Felman P, Berger F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002;3:41-47.
17. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206-209.
18. Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89-94.
19. Muir AJ, Birnstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non Hispanic whites. N Engl J Med. 2004;350:2265-2271.
20. Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood. 2003;102:996-999.
21. Camacho FI, Mollejo M, Mateo MS, et al. Progression to large B-cell lymphoma in splenic marginal zone lymphoma: a description of a series of 12 cases. Am J Surg Pathol. 2001;25:1268-1276.
22. Thomas DA, O'Brien S, Cortes J, et al. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab [abstract]. Blood. 2001;98:134.
23. Arcaini L, Orlandi E, Scotti M, et al. Combination of rituximab, cyclophosphamide and vincristine induces complete haematologic remission of splenic marginal zone lymphoma. Clin Lymphoma. 2004;4:250-252.
24. Sharma K, Dave HP, Siegel RS, Schechter JP. Rituximab for treatment of splenic lymphoma with villous lymphocytes [abstract]. Blood. 2003;102(Suppl 1):4954.
25. Franco V, Florena AM, Stella M, et al. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer. 2001;91:294-301.